Prosensa’s Failure Will Not Justify Buying Sarepta

Recently, shares of Prosensa (NASDAQ: RNA) dropped 70% after announcing the negative outcome from its phase III study of an experimental drug, Drisapersen. Meanwhile Sarepta Therapeutics (NASDAQ: SRPT) has seen a significant increase in their market capitalization. Prosensa’s primary focus has been developing therapeutics that treat rare neuromuscular and neurodegenerative disorders. Currently, its product portfolio consists of six potential […]